The PennZone

PITTSBURGH, Aug. 6, 2024 ~ Journalist: MolecuLight Corp., a leading company in fluorescence imaging technology for detecting harmful bacteria in wound care, has recently announced the publication of a peer-reviewed clinical research study showcasing the transformative capabilities of their technology. The study, conducted on 167 Medicare beneficiaries across 55 Long Term Care (LTC) and Skilled Nursing Facilities (SNF) in the US, highlights the significant improvements in pressure injury outcomes and infection control achieved with the use of MolecuLight.

The article, titled "Improving Wound Healing and Infection Control in Long-term Care with Bacterial Fluorescence Imaging," was published by Martha R. Kelso and her colleagues in the latest edition of Advances in Skin & Wound Care journal. The researchers reported impressive results, showing a remarkable improvement in pressure injury outcomes among patients with complex healing challenges. This serves as a testament to the effectiveness of MolecuLight technology, even in the most challenging patient cases.

More on The PennZone

• Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
• New School Announces Student Enrollment
• Able Rooter Expands Services to Offer Premium Water Heater Installation Across St. Louis
• Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
• J. Kenton Pierce Wins Prometheus Award for Best Novel

The study compared outcomes between patients who received standard care alone and those who had MolecuLight real-time fluorescence integrated into their treatment plan. The results showed that patients who were imaged with MolecuLight saw a 71% increase in wound healing by 12 weeks, healed 28% faster, and were 1.8 times more likely to heal their wound within this time frame. Additionally, there was a significant decrease (75%) in severe infection complications such as cellulitis, osteomyelitis, gangrene, sepsis, and wound-related hospitalization when MolecuLight was used to guide patient care.

Lead author Martha R. Kelso expressed her excitement about these findings stating, "We are very excited to share with the world through concrete findings what we have been experiencing firsthand with our LTC/SNF patients." She further added that "the positive effects that the MolecuLight technology has on all patients, even those who are severely sick and compromised, is outstanding. Increasing healing rates, shortening healing times, and avoiding complications is how you make a difference. All patients deserve the best!"

More on The PennZone

• Ezra Wohlgelernter Named as a 2026 Philadelphia Power Broker by City & State PA
• Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival
• Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
• Brett Furman Launches Ranks Grow
• Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love

Anil Amlani, CEO of MolecuLight, also shared his enthusiasm for these groundbreaking results. "We are thrilled to see such compelling evidence of the impact our technology can have on patient outcomes, particularly in such a vulnerable and systematically neglected patient population." He emphasized that "the significant improvements in wound healing and the dramatic reduction in infection complications underscore the potential of MolecuLight to revolutionize wound care, in any place of service and against the most challenging of clinical backgrounds."

This research serves as another example of MolecuLight's commitment to improving patient care and advancing the field of wound management. With these remarkable outcomes now published in a peer-reviewed journal, it is hoped that more healthcare professionals will adopt this technology to provide better care for their patients.

---

Show All News | Disclaimer | Report Violation